METHODS FOR MEASURING PLATELET REACTIVITY OF INDIVIDUALS TREATED WITH DRUG ELUTING STENTS
First Claim
1. A method for measuring inhibition of platelet reactivity by a P2Y12 antagonist in an individual treated with a drug-eluting stent (DES), comprising the steps of:
- a) providing a platelet containing blood sample from an individual treated with a DES and a P2Y12 antagonist;
b) contacting said platelet containing blood sample with particles comprising a GPIIb/IIIa receptor ligand immobilized thereon, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1) under conditions suitable for agglutination of said particles mediated by said platelet in said blood sample; and
c) assessing said agglutination to determine the presence, absence and/or degree of inhibition of platelet aggregation by said P2Y12 antagonist in said individual, wherein absence or a reduction of said agglutination indicates that said individual has reduced platelet reactivity in response to said P2Y12 antagonist treatment.
9 Assignments
0 Petitions
Accused Products
Abstract
A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.
-
Citations
25 Claims
-
1. A method for measuring inhibition of platelet reactivity by a P2Y12 antagonist in an individual treated with a drug-eluting stent (DES), comprising the steps of:
-
a) providing a platelet containing blood sample from an individual treated with a DES and a P2Y12 antagonist; b) contacting said platelet containing blood sample with particles comprising a GPIIb/IIIa receptor ligand immobilized thereon, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1) under conditions suitable for agglutination of said particles mediated by said platelet in said blood sample; and c) assessing said agglutination to determine the presence, absence and/or degree of inhibition of platelet aggregation by said P2Y12 antagonist in said individual, wherein absence or a reduction of said agglutination indicates that said individual has reduced platelet reactivity in response to said P2Y12 antagonist treatment. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
-
2. A method for identifying an individual treated with a drug-eluting stent (DES) at risk for stent thrombosis, comprising the steps of:
-
a) providing a platelet containing blood sample from an individual treated with a DES and a P2Y12 antagonist; b) contacting said platelet containing blood sample with particles comprising a GPIIb/IIIa receptor ligand immobilized thereon, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1) under conditions suitable for agglutination of said particles mediated by said platelet in said blood sample; c) assessing said agglutination to determine the presence, absence and/or degree of inhibition of platelet aggregation by said P2Y12 antagonist in said individual, wherein absence or a reduction of said agglutination indicates that said individual has reduced platelet reactivity in response to said P2Y12 antagonist treatment; and d) assessing a risk level of said individual for stent thrombosis.
-
- 20. A kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist in an individual treated with a drug-eluting stent (DES), comprising a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1).
Specification